Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 2/2017

01-04-2017 | Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (A Hasan, Section Editor)

Percutaneous Ventricular Restoration with a Partitioning Device for Ischemic Heart Failure Treatment

Authors: Bishnu P. Dhakal, Guilherme H. Oliveira

Published in: Current Heart Failure Reports | Issue 2/2017

Login to get access

Abstract

Purpose of the review

Percutaneous ventricular restoration with a ventricular partitioning device (VPD) is a novel minimally invasive procedure designed to restore the left ventricular (LV) shape by isolating the infarcted and aneurysmal LV apex from remainder of the cavity in heart failure patients with severely reduced LV ejection fraction. In this review, we perform an in-depth analysis of the design and purpose of the VPD and review the available clinical data, with special attention to hemodynamics, outcomes, and complications.

Recent findings

PARACHUTE trials have shown >90% procedural success rate of VPD implant. Heart failure patients had improvement in hemodynamics (reduction in LV volumes and increase in LV ejection fraction) and functional status (6-min walking distance and quality of life scores) after the VPD implant. Optimal implant position is necessary to obtain a good clinical outcome.

Summary

Percutaneous VPD implantation has thus far been a safe intervention capable of improving surrogate markers of heart failure but there is still a need to develop more durable devices with a long-lasting hemodynamics effect.
Appendix
Available only for authorised users
Literature
1.
• Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart Disease and Stroke Statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–360. This report from American Heart Association has the most up-to-date statistics related to heart disease, stroke, and other cardiovascular and metabolic diseases.CrossRef
2.
•• Oliveira GH, Al-Kindi SG, Bezerra HG, Costa MA. Left ventricular restoration devices. J Cardiovasc Transl Res. 2014;7(3):282–91. This review has a nice summary of surgical and minimally invasive methods of left ventricular restoration.CrossRefPubMed
3.
Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4(1):98–108.CrossRefPubMed
4.
Rouleau JL, de Champlain J, Klein M, Bichet D, Moye L, Packer M, et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol. 1993;22(2):390–8.CrossRefPubMed
5.
Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161–72.CrossRefPubMed
6.
McKay RG, Pfeffer MA, Pasternak RC, Markis JE, Come PC, Nakao S, et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation. 1986;74(4):693–702.CrossRefPubMed
7.
Chareonthaitawee P, Christian TF, Hirose K, Gibbons RJ, Rumberger JA. Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction. J Am Coll Cardiol. 1995;25(3):567–73.CrossRefPubMed
8.
9.
Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101(25):2981–8.CrossRefPubMed
10.
Remme WJ. Therapeutic strategies and neurohormonal control in heart failure. Eur Heart J. 1994;15 Suppl D:129–38.CrossRefPubMed
11.
12.
Pouleur HG, Konstam MA, Udelson JE, Rousseau MF. Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. The SOLVD Investigators. J Am Coll Cardiol. 1993;22(4 Suppl A):43A–8A.CrossRefPubMed
13.
Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91(10):2573–81.CrossRefPubMed
14.
Konstam MA, Patten RD, Thomas I, Ramahi T, La Bresh K, Goldman S, et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J. 2000;139(6):1081–7.CrossRefPubMed
15.
Senior R, Basu S, Kinsey C, Schaeffer S, Lahiri A. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J. 1999;137(4 Pt 1):646–52.CrossRefPubMed
16.
Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996;94(11):2800–6.CrossRefPubMed
17.
Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation. 1997;96(7):2197–205.CrossRefPubMed
18.
Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36(7):2072–80.CrossRefPubMed
19.
Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006;367(9507):356–67.CrossRefPubMed
20.
Di Donato M, Sabatier M, Toso A, Barletta G, Baroni M, Dor V, et al. Regional myocardial performance of non-ischaemic zones remote from anterior wall left ventricular aneurysm. Effects of aneurysmectomy. Eur Heart J. 1995;16(9):1285–92.CrossRefPubMed
21.
22.
Chen WY, Wu FY, Shih CC, Lai ST, Hsu CP. Left ventricular aneurysm repair: a comparison of linear versus patch remodeling. J Chin Med Assoc. 2009;72(8):414–21.CrossRefPubMed
23.
Prucz RB, Weiss ES, Patel ND, Nwakanma LU, Baumgartner WA, Conte JV. Coronary artery bypass grafting with or without surgical ventricular restoration: a comparison. Ann Thorac Surg. 2008;86(3):806–14. discussion -14.CrossRefPubMed
24.
25.
26.
Likoff W, Bailey CP. Ventriculoplasty: excision of myocardial aneurysm; report of a successful case. J Am Med Assoc. 1955;158(11):915–20.CrossRefPubMed
27.
Cooley DA, Collins HA, Morris Jr GC, Chapman DW. Ventricular aneurysm after myocardial infarction; surgical excision with use of temporary cardiopulmonary bypass. J Am Med Assoc. 1958;167(5):557–60.CrossRefPubMed
28.
Jatene AD. Left ventricular aneurysmectomy. Resection or reconstruction. J Thorac Cardiovasc Surg. 1985;89(3):321–31.PubMed
29.
Dor V, Saab M, Coste P, Kornaszewska M, Montiglio F. Left ventricular aneurysm: a new surgical approach. Thorac Cardiovasc Surg. 1989;37(1):11–9.CrossRefPubMed
30.
Di Donato M, Barletta G, Maioli M, Fantini F, Coste P, Sabatier M, et al. Early hemodynamic results of left ventricular reconstructive surgery for anterior wall left ventricular aneurysm. Am J Cardiol. 1992;69(9):886–90.CrossRefPubMed
31.
Mann DL, Acker MA, Jessup M, Sabbah HN, Starling RC, Kubo SH, et al. Clinical evaluation of the CorCap Cardiac Support Device in patients with dilated cardiomyopathy. Ann Thorac Surg. 2007;84(4):1226–35.CrossRefPubMed
32.
Costanzo MR, Ivanhoe RJ, Kao A, Anand IS, Bank A, Boehmer J, et al. Prospective evaluation of elastic restraint to lessen the effects of heart failure (PEERLESS-HF) trial. J Card Fail. 2012;18(6):446–58.CrossRefPubMed
33.
Grossi EA, Patel N, Woo YJ, Goldberg JD, Schwartz CF, Subramanian V, et al. Outcomes of the RESTOR-MV Trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve). J Am Coll Cardiol. 2010;56(24):1984–93.CrossRefPubMed
34.
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607–16.CrossRefPubMedPubMedCentral
35.
Shroyer AL, Collins JF, Grover FL. Evaluating clinical applicability: the STICH trial’s findings. J Am Coll Cardiol. 2010;56(6):508–9.CrossRefPubMed
36.
• Ige M, Al-Kindi SG, Attizzani G, Costa M, Oliveira GH. Percutaneous left ventricular restoration. Heart Fail Clin. 2015;11(2):261–73. This review summarizes the methods of ventricular restoration and various PARACHUTE trial results.CrossRefPubMed
37.
Skowasch M, Robertson GC, Wunderlich N, Nikolic S, Khairkhahan A, Sievert H. Percutaneous ventricular restoration in a chronic heart failure patient. EuroIntervention. 2006;2(1):128–31.PubMed
38.
• Costa MA, Pencina M, Nikolic S, Engels T, Templin B, Abraham WT. The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the Parachute device in patients with ischemic heart failure and dilated left ventricles. Am Heart J. 2013;165(4):531–6. This paper reviews the design of PARACHUTE IV trial.CrossRefPubMed
39.
Nikolic SD, Khairkhahan A, Ryu M, Champsaur G, Breznock E, Dae M. Percutaneous implantation of an intraventricular device for the treatment of heart failure: experimental results and proof of concept. J Card Fail. 2009;15(9):790–7.CrossRefPubMed
40.
Otasevic P, Sagic D, Antonic Z, Nikolic SD, Khairakhan A, Radovancevic B, et al. First-in-man implantation of left ventricular partitioning device in a patient with chronic heart failure: twelve-month follow-up. J Card Fail. 2007;13(7):517–20.CrossRefPubMed
41.
Sharkey H, Nikolic S, Khairkhahan A, Dae M. Left ventricular apex occluder. Description of a ventricular partitioning device. EuroIntervention. 2006;2(1):125–7.PubMed
42.
Mazzaferri Jr EL, Gradinac S, Sagic D, Otasevic P, Hasan AK, Goff TL, et al. Percutaneous left ventricular partitioning in patients with chronic heart failure and a prior anterior myocardial infarction: results of the PercutAneous Ventricular RestorAtion in Chronic Heart failUre PaTiEnts Trial. Am Heart J. 2012;163(5):812–20. e1.CrossRefPubMed
43.
Costa MA, Mazzaferri Jr EL, Sievert H, Abraham WT. Percutaneous ventricular restoration using the Parachute device in patients with ischemic heart failure: three-year outcomes of the PARACHUTE first-in-human study. Circ Heart Fail. 2014;7(5):752–8.CrossRefPubMed
44.
Thomas M, Nienaber CA, Ince H, Erglis A, Vukcevic V, Schafer U, et al. Percutaneous ventricular restoration (PVR) therapy using the Parachute device in 100 subjects with ischaemic dilated heart failure: one-year primary endpoint results of PARACHUTE III, a European trial. EuroIntervention. 2015;11(6):710–7.CrossRefPubMed
45.
• Yang YJ, Huo Y, Xu YW, Wang JA, Han YL, Ge JB, et al. Percutaneous ventricular restoration therapy using the Parachute device in Chinese patients with ischemic heart failure: three-month primary end-point results of PARACHUTE China study. Chin Med J (Engl). 2016;129(17):2058–62. PARACHUTE China trial results. CrossRef
46.
Sagic D, Otasevic P, Sievert H, Elsasser A, Mitrovic V, Gradinac S. Percutaneous implantation of the left ventricular partitioning device for chronic heart failure: a pilot study with 1-year follow-up. Eur J Heart Fail. 2010;12(6):600–6.CrossRefPubMed
47.
Silva G, Melica B, Pires de Morais G, Sousa O, Bettencourt N, Ribeiro J, et al. Percutaneous implantation of a ventricular partitioning device for treatment of ischemic heart failure: initial experience of a center. Rev Port Cardiol. 2012;31(12):795–801.PubMed
48.
• Schmidt T, Frerker C, Thielsen T, Dotz I, Wohlmuth P, Kuck KH, et al. New evidence for favourable effects on haemodynamics and ventricular performance after Parachute((R)) implantation in humans. Eur J Heart Fail. 2014;16(10):1112–9. This study highlights the acute hemodynamic effects of percutaneous ventricular partitioning device implantation.CrossRefPubMed
49.
Schäfer U. Percutaneous ventricular restoration (PVR) therapy using the Parachute® device in patients with ischemic dilated heart failure: PARACHUTE III, European post market trial, 2 year results. Transcatheter Cardiovascular Therapeutics (TCT). 2015
50.
Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J. 2011;32(2):205–17.CrossRefPubMed
51.
Adamson P, Thomas M, Costa M, Nienaber C, Ince H, Erglis A, et al. Pooled analysis of percutaneous ventricular restoration (PVR) therapy using the PARACHUTE® device in patients with ischemic dilated heart failure. J Am Coll Cardiol. 2014; 63 (12_S).
52.
Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011;306(15):1669–78.CrossRefPubMedPubMedCentral
53.
Bozdag-Turan I, Bermaoui B, Turan RG, Kische S, Paranskaya L, Kloker K, et al. Parachute implant: CT morphological criteria of our center to identify the suitable patient. Cardiovasc Ther. 2014;32(1):26–31.CrossRefPubMed
54.
Bozdag-Turan I, Bermaoui B, Paranskaya L, GokmenTuran R, D’Ancona G, Kische S, et al. Challenges in patient selection for the Parachute device implantation. Catheter Cardiovasc Interv. 2013;82(5):E718–25.CrossRefPubMed
55.
• Alaiti MA, Fares A, Erglis A, Nshisso L, Shaikh K, DeCicco AE, et al. Evaluating the quality of implantation of percutaneous ventricular restoration device (Parachute®) by cardiac computed tomography. Catheter Cardiovasc Interv. 2017 doi: 10.​1002/​ccd.​26644. This study demonstrates the importance of optimal positioning of the ventricular partitioning device implant to achieve good treatment outcomes.
56.
Tam CC, Fares A, Alaiti A, Shaikh K, Ince H, Erglis A, et al. Cardiac computed tomography assessment of the near term impact of percutaneous ventricular restoration therapy (Parachute((R)) ) on mitral valve geometry. Catheter Cardiovasc Interv. 2016;88(2):E45–51.CrossRefPubMed
57.
Zhou D, Pan W, Guan L, Pan C, Ge J. Transcatheter closure of a post-myocardial infarction ventricular septal rupture using a Parachute device. JACC Cardiovasc Interv. 2015;8(2):369–71.CrossRefPubMed
58.
Abu Saleh WK, Al Jabbari O, Bruckner BA, Suarez EE, Estep JD, Loebe M. Left ventricular assist device implantation after intracardiac Parachute device removal. Ann Thorac Surg. 2015;100(2):720–2.CrossRefPubMed
59.
Ravi Y, Bansal S, Rosas PC, Mazzaferri Jr EL, Sai-Sudhakar CB. Surgical considerations for the explantation of the Parachute left ventricular partitioning device and the implantation of the HeartMate II left ventricular assist device. Proc (Bayl Univ Med Cent). 2016;29(2):176–7.
60.
Lauschke J, Schneider R, Bansch D. Ventricular tachycardia ablation in a patient with a Parachute device: a decent word of warning. Europace. 2014;16(2):207.CrossRefPubMed
61.
Ladich E, Otsuka F, Virmani R. A pathologic study of explanted Parachute devices from seven heart failure patients following percutaneous ventricular restoration. Catheter Cardiovasc Interv. 2014;83(4):619–30.CrossRefPubMed
Metadata
Title
Percutaneous Ventricular Restoration with a Partitioning Device for Ischemic Heart Failure Treatment
Authors
Bishnu P. Dhakal
Guilherme H. Oliveira
Publication date
01-04-2017
Publisher
Springer US
Published in
Current Heart Failure Reports / Issue 2/2017
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-017-0326-z

Other articles of this Issue 2/2017

Current Heart Failure Reports 2/2017 Go to the issue

Biomarkers of Heart Failure (W H W Tang and J Grodin, Section Editors)

Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives

Self-Care and Health Outcomes (R Gallagher and R Clark, Section Editors)

Role of the Pharmacist for Improving Self-care and Outcomes in Heart Failure

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S Katz, Section Editor)

Orexin: a Missing Link Between Sleep Disorders and Heart Failure?

Clinical Trials (J Butler, Section Editor)

Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions

Pharmacologic Therapy (W H W Tang, Section Editor)

Diuretic Strategies in Acute Decompensated Heart Failure

Self-Care and Health Outcomes (R Gallagher and R Clark, Section Editors)

Factors Related to Self-Care in Heart Failure Patients According to the Middle-Range Theory of Self-Care of Chronic Illness: a Literature Update
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits